Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now?

Core Viewpoint - Hologic (HOLX) has been trending in stock searches, with a recent performance of +2.7% over the past month, outperforming the S&P 500's +1.1% and the Zacks Medical - Instruments industry's -6.2% [1] Earnings Estimates - For the current quarter, Hologic is expected to report earnings of $1.10 per share, reflecting an increase of +8.9% year-over-year, although the Zacks Consensus Estimate has decreased by -0.3% in the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $4.24, indicating a +3.9% change from the previous year, with a slight decrease of -0.1% over the last month [4] - For the next fiscal year, the consensus estimate is $4.48, showing a +5.6% increase from the prior year, with no change in the estimate over the past month [5] Revenue Growth - Hologic's consensus sales estimate for the current quarter is $1.03 billion, representing a year-over-year increase of +4.7% [10] - The sales estimates for the current and next fiscal years are $4.08 billion and $4.26 billion, indicating changes of +1.4% and +4.3%, respectively [10] Recent Performance and Surprise History - In the last reported quarter, Hologic achieved revenues of $1.02 billion, a +1.2% increase year-over-year, and an EPS of $1.08, compared to $1.06 a year ago [11] - The company surpassed consensus EPS estimates three times and revenue estimates three times over the last four quarters [12] Valuation - Hologic is graded B in the Zacks Value Style Score, suggesting it is trading at a discount compared to its peers [16]